首页 > 最新文献

International journal of clinical pharmacology & toxicology最新文献

英文 中文
Hypoxia alters P-gp Expression and Activity in Three Different Rat Intestinal Modles: Implications for Levofloxacin Delivery 缺氧改变P-gp在三种不同大鼠肠道模型中的表达和活性:对左氧氟沙星给药的意义
Pub Date : 2021-06-22 DOI: 10.19070/2167-910x-2100052
Y. Xi
{"title":"Hypoxia alters P-gp Expression and Activity in Three Different Rat Intestinal Modles: Implications for Levofloxacin Delivery","authors":"Y. Xi","doi":"10.19070/2167-910x-2100052","DOIUrl":"https://doi.org/10.19070/2167-910x-2100052","url":null,"abstract":"","PeriodicalId":91507,"journal":{"name":"International journal of clinical pharmacology & toxicology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48111555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CYP2B6 Genotype Guided Dosing of Propofol Anesthesia in the Elderly based on Nonparametric Population Pharmacokinetic Modeling and Simulations. 基于非参数人群药代动力学模型和模拟的CYP2B6基因型引导老年人给药异丙酚麻醉。
Pub Date : 2017-01-01 DOI: 10.19070/2167-910X-1700041
A. Eugene
OBJECTIVE The primary aim of this article is to test the hypothesis that nonparametric pharmacometric modeling will accurately identify CYP2B6 genotype subgroups based on data from a study that reported results based on parametric pharmacokinetics (PK). METHODS Propofol concentration-time data were originally reported in the Kansaku et al. 2011 publication. Nonparametric Nonlinear Mixed Effects Modeling (NLME) was conducted using the PMETRICS R package while population pharmacokinetic model parameters were estimated using a FORTRAN compiler. Finally, model-based dosing simulations were conducted in the MATLAB Simbiology. RESULTS A total of 51 patients were included in the final PK analysis. A two-compartment gamma multiplicative error model adequately described the propofol concentration-time data. The precision of the goodness-of-fit plots resulted in an R2 of 0.927 and an R2 of 0.992 for the population prediction and individual predictions, respectively. Neither the UGT1A9 nor the CYP2B6 G516T gene variants resulted in statistically significant PK parameter differences while the CYP2B6 A785G gene variants resulted in statistically significant differences for the elimination rate. Model-based dosing-simulations comparing patients with the CYP2B6 AA & AG genotypes to both GG genotypes and patients from a multicenter trial suggest a 50% decrease in propofol infusion dose, to 25mg/kg/min, be made to result in approximately equivalent drug exposures. CONCLUSION Based on the pharmacometric modeling and simulation, if no dosage adjustments are made for the elderly CYP2B6 AA and AG genotypes, a 250% higher propofol blood exposure will be evident within 1-hour from the start of the infusion. Thus, based on the pharmacokinetic model, genotyping elderly patients for the CYP2B6 AA and AG gene variants will decrease the total propofol blood exposure during anesthesia and sedation when an infusion dose adjustment is made to 25mg/kg/min.
本文的主要目的是验证基于参数药代动力学(PK)结果的研究数据的非参数药物计量模型将准确识别CYP2B6基因型亚组的假设。方法异丙酚浓度-时间数据最初报告于Kansaku等人2011年的出版物。使用PMETRICS R软件包进行非参数非线性混合效应建模(NLME),使用FORTRAN编译器估计群体药代动力学模型参数。最后,在MATLAB Simbiology中进行了基于模型的加药仿真。结果共51例患者纳入最终的PK分析。双室伽马乘法误差模型充分描述了异丙酚浓度-时间数据。拟合优度图的总体预测和个体预测的R2分别为0.927和0.992。UGT1A9和CYP2B6 G516T基因变异对PK参数差异均无统计学意义,而CYP2B6 A785G基因变异对淘汰率差异均无统计学意义。基于模型的剂量模拟将CYP2B6 AA和AG基因型患者与GG基因型患者以及来自多中心试验的患者进行比较,结果表明,异丙酚输注剂量减少50%,至25mg/kg/min,可导致大致相等的药物暴露。结论基于药理学模型和模拟,如果不调整CYP2B6 AA和AG基因型老年人的剂量,在开始输注后1小时内异丙酚血暴露量明显增加250%。因此,基于药代动力学模型,将老年患者CYP2B6 AA和AG基因变异进行基因分型,当输注剂量调整为25mg/kg/min时,麻醉和镇静期间异丙酚总血暴露量会减少。
{"title":"CYP2B6 Genotype Guided Dosing of Propofol Anesthesia in the Elderly based on Nonparametric Population Pharmacokinetic Modeling and Simulations.","authors":"A. Eugene","doi":"10.19070/2167-910X-1700041","DOIUrl":"https://doi.org/10.19070/2167-910X-1700041","url":null,"abstract":"OBJECTIVE The primary aim of this article is to test the hypothesis that nonparametric pharmacometric modeling will accurately identify CYP2B6 genotype subgroups based on data from a study that reported results based on parametric pharmacokinetics (PK). METHODS Propofol concentration-time data were originally reported in the Kansaku et al. 2011 publication. Nonparametric Nonlinear Mixed Effects Modeling (NLME) was conducted using the PMETRICS R package while population pharmacokinetic model parameters were estimated using a FORTRAN compiler. Finally, model-based dosing simulations were conducted in the MATLAB Simbiology. RESULTS A total of 51 patients were included in the final PK analysis. A two-compartment gamma multiplicative error model adequately described the propofol concentration-time data. The precision of the goodness-of-fit plots resulted in an R2 of 0.927 and an R2 of 0.992 for the population prediction and individual predictions, respectively. Neither the UGT1A9 nor the CYP2B6 G516T gene variants resulted in statistically significant PK parameter differences while the CYP2B6 A785G gene variants resulted in statistically significant differences for the elimination rate. Model-based dosing-simulations comparing patients with the CYP2B6 AA & AG genotypes to both GG genotypes and patients from a multicenter trial suggest a 50% decrease in propofol infusion dose, to 25mg/kg/min, be made to result in approximately equivalent drug exposures. CONCLUSION Based on the pharmacometric modeling and simulation, if no dosage adjustments are made for the elderly CYP2B6 AA and AG genotypes, a 250% higher propofol blood exposure will be evident within 1-hour from the start of the infusion. Thus, based on the pharmacokinetic model, genotyping elderly patients for the CYP2B6 AA and AG gene variants will decrease the total propofol blood exposure during anesthesia and sedation when an infusion dose adjustment is made to 25mg/kg/min.","PeriodicalId":91507,"journal":{"name":"International journal of clinical pharmacology & toxicology","volume":"6 1 1","pages":"242-249"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68338016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Identifying Treatment Response of Sertraline in a Teenager with Selective Mutism using Electrophysiological Neuroimaging. 应用电生理神经成像技术鉴别舍曲林治疗选择性缄默症的疗效。
Pub Date : 2016-06-01 DOI: 10.19070/2167-910X-1600036
A. Eugene, J. Masiak
BACKGROUNDSelective Mutism is described as the inability to verbally express oneself in anxiety provoking social situations and may result in awkward social interactions in school-aged children. In this case-report we present the baseline electrophysiological neuroimaging results and after treatment with Sertraline for 6-weeks.METHODSA 20-channel EEG event-related potential recording was acquired during an internal voice task at baseline prior to the initiation of 50mg of Sertraline and then repeated 6-weeks after treatment with Sertraline. EEG signals were processed for movement, eye-blink, and muscle artifacts and ERP signal averaging was completed. ERPs were analyzed using Standard Low Resolution Brain Electromagnetic Tomography (sLORETA).RESULTSAt baseline, Sertraline increased the neuronal activation in the middle temporal gyrus and the anterior cingulate gyrus from baseline in the patient following 6-weeks of treatment.CONCLUSIONOur findings suggest that electrophysiological neuroimaging may provide a creative approach for personalizing medicine by providing insight to the pharmacodynamics of antidepressants.
选择性缄默症被描述为在令人焦虑的社交场合无法用语言表达自己,并可能导致学龄儿童社交尴尬。在本病例报告中,我们介绍了基线电生理神经成像结果和使用舍曲林治疗6周后的结果。方法在开始使用舍曲林50mg之前,在基线的内部语音任务中获取20通道脑电图事件相关电位记录,并在舍曲林治疗6周后重复记录。对脑电信号进行运动、眨眼和肌肉伪影处理,并对ERP信号进行平均处理。采用标准低分辨率脑电磁断层扫描(sLORETA)分析erp。结果在治疗6周后,舍曲林使患者颞中回和前扣带回的神经元活性较基线增加。结论:神经电生理成像技术通过深入了解抗抑郁药物的药效学,为个性化用药提供了一种创新的方法。
{"title":"Identifying Treatment Response of Sertraline in a Teenager with Selective Mutism using Electrophysiological Neuroimaging.","authors":"A. Eugene, J. Masiak","doi":"10.19070/2167-910X-1600036","DOIUrl":"https://doi.org/10.19070/2167-910X-1600036","url":null,"abstract":"BACKGROUND\u0000Selective Mutism is described as the inability to verbally express oneself in anxiety provoking social situations and may result in awkward social interactions in school-aged children. In this case-report we present the baseline electrophysiological neuroimaging results and after treatment with Sertraline for 6-weeks.\u0000\u0000\u0000METHODS\u0000A 20-channel EEG event-related potential recording was acquired during an internal voice task at baseline prior to the initiation of 50mg of Sertraline and then repeated 6-weeks after treatment with Sertraline. EEG signals were processed for movement, eye-blink, and muscle artifacts and ERP signal averaging was completed. ERPs were analyzed using Standard Low Resolution Brain Electromagnetic Tomography (sLORETA).\u0000\u0000\u0000RESULTS\u0000At baseline, Sertraline increased the neuronal activation in the middle temporal gyrus and the anterior cingulate gyrus from baseline in the patient following 6-weeks of treatment.\u0000\u0000\u0000CONCLUSION\u0000Our findings suggest that electrophysiological neuroimaging may provide a creative approach for personalizing medicine by providing insight to the pharmacodynamics of antidepressants.","PeriodicalId":91507,"journal":{"name":"International journal of clinical pharmacology & toxicology","volume":"5 4 1","pages":"216-219"},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68337956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Identifying Treatment Response of Sertraline in a Teenager with Selective Mutism using Electrophysiological Neuroimaging. 应用电生理神经成像技术鉴别舍曲林治疗选择性缄默症的疗效。
Pub Date : 2016-06-01 Epub Date: 2016-06-15
Andy R Eugene, Jolanta Masiak

Background: Selective Mutism is described as the inability to verbally express oneself in anxiety provoking social situations and may result in awkward social interactions in school-aged children. In this case-report we present the baseline electrophysiological neuroimaging results and after treatment with Sertraline for 6-weeks.

Methods: A 20-channel EEG event-related potential recording was acquired during an internal voice task at baseline prior to the initiation of 50mg of Sertraline and then repeated 6-weeks after treatment with Sertraline. EEG signals were processed for movement, eye-blink, and muscle artifacts and ERP signal averaging was completed. ERPs were analyzed using Standard Low Resolution Brain Electromagnetic Tomography (sLORETA).

Results: At baseline, Sertraline increased the neuronal activation in the middle temporal gyrus and the anterior cingulate gyrus from baseline in the patient following 6-weeks of treatment.

Conclusion: Our findings suggest that electrophysiological neuroimaging may provide a creative approach for personalizing medicine by providing insight to the pharmacodynamics of antidepressants.

背景:选择性缄默症被描述为在引起焦虑的社交场合中无法用语言表达自己,并可能导致学龄儿童社交尴尬。在本病例报告中,我们介绍了基线电生理神经成像结果和使用舍曲林治疗6周后的结果。方法:在开始使用舍曲林50mg之前,在基线的内部语音任务中获得20通道脑电图事件相关电位记录,然后在舍曲林治疗6周后重复记录。对脑电信号进行运动、眨眼和肌肉伪影处理,并对ERP信号进行平均处理。采用标准低分辨率脑电磁断层扫描(sLORETA)分析erp。结果:在基线时,舍曲林增加了患者在治疗6周后的颞中回和前扣带回的神经元激活。结论:我们的研究结果表明,神经电生理成像可以通过洞察抗抑郁药的药效学,为个性化药物提供一种创造性的方法。
{"title":"Identifying Treatment Response of Sertraline in a Teenager with Selective Mutism using Electrophysiological Neuroimaging.","authors":"Andy R Eugene,&nbsp;Jolanta Masiak","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Selective Mutism is described as the inability to verbally express oneself in anxiety provoking social situations and may result in awkward social interactions in school-aged children. In this case-report we present the baseline electrophysiological neuroimaging results and after treatment with Sertraline for 6-weeks.</p><p><strong>Methods: </strong>A 20-channel EEG event-related potential recording was acquired during an internal voice task at baseline prior to the initiation of 50mg of Sertraline and then repeated 6-weeks after treatment with Sertraline. EEG signals were processed for movement, eye-blink, and muscle artifacts and ERP signal averaging was completed. ERPs were analyzed using Standard Low Resolution Brain Electromagnetic Tomography (sLORETA).</p><p><strong>Results: </strong>At baseline, Sertraline increased the neuronal activation in the middle temporal gyrus and the anterior cingulate gyrus from baseline in the patient following 6-weeks of treatment.</p><p><strong>Conclusion: </strong>Our findings suggest that electrophysiological neuroimaging may provide a creative approach for personalizing medicine by providing insight to the pharmacodynamics of antidepressants.</p>","PeriodicalId":91507,"journal":{"name":"International journal of clinical pharmacology & toxicology","volume":"5 4","pages":"216-219"},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959607/pdf/nihms796654.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34322789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations. 基于性别的老年人美托洛尔给药的人群药代动力学模型和模拟。
Pub Date : 2016-05-01 Epub Date: 2016-05-19
Andy R Eugene

Introduction: This article seeks to clarify if gender-based differences occur in the pharmacokinetics of metoprolol in the elderly patients. There are a series of physiologic changes that occur in the elderly ranging from decreased hepatic blood flow to increased adiposity causing higher plasma concentrations at therapeutic doses as compared to the healthy young population.

Methods: Population pharmacokinetic modeling were performed using MONOLIX and Monte-Carlo simulations were conducted using MATLAB. The data was based from a previously published dataset where elderly patients, having multiple comorbidities, were administered a 50mg dose of metoprolol.

Results: Metoprolol was modeled using a one-compartment model and resulted in the following population pharmacokinetic parameters: volume of distribution, V=38L (CV=155%), clearance rates, CL-Men=105L/hour and CL-Women=59.1L/hour (38%), time lag, Tlag=0.469 hour (CV=17%), and the absorption rate constant, Ka=0.235 hr-1 (CV=23%).

Conclusion: Gender stratified doses resulting in an equivalent systemic metoprolol exposure in geriatric patients have been identified. Metoprolol doses resulting a similar AUC in a healthy young male administered 50mg tablet were 15mg for geriatric women and 25mg for geriatric men. Further, Metoprolol doses of 25mg for geriatric women and 50mg for geriatric men resulted in an equivalent AUC to a healthy young males dosed with a 100mg tablet. A 15mg Metoprolol tablet may need to be compounded to account for the gender differences in Metoprolol pharmacokinetics.

简介:本文旨在澄清老年患者美托洛尔的药代动力学是否存在性别差异。与健康的年轻人群相比,在治疗剂量下,老年人发生一系列生理变化,从肝血流量减少到肥胖增加,导致血浆浓度升高。方法:采用MONOLIX软件建立种群药代动力学模型,采用MATLAB软件进行蒙特卡罗模拟。该数据基于先前发表的数据集,其中患有多种合并症的老年患者给予50mg剂量的美托洛尔。结果:美托洛尔采用单室模型建模,得到的群体药动学参数为:分布容积V=38L (CV=155%),清除率cl -男性=105L/h, cl -女性=59.1L/h(38%),时间滞后,lag=0.469 h (CV=17%),吸收常数Ka=0.235 hr-1 (CV=23%)。结论:性别分层剂量导致老年患者全身美托洛尔暴露的等效已被确定。美托洛尔剂量对健康年轻男性的AUC相似,给予50mg片剂的老年女性为15mg,老年男性为25mg。此外,老年女性服用25毫克美托洛尔,老年男性服用50毫克美托洛尔,其AUC与健康年轻男性服用100毫克片剂的AUC相当。15mg美托洛尔片可能需要复合,以解释美托洛尔药代动力学的性别差异。
{"title":"Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations.","authors":"Andy R Eugene","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>This article seeks to clarify if gender-based differences occur in the pharmacokinetics of metoprolol in the elderly patients. There are a series of physiologic changes that occur in the elderly ranging from decreased hepatic blood flow to increased adiposity causing higher plasma concentrations at therapeutic doses as compared to the healthy young population.</p><p><strong>Methods: </strong>Population pharmacokinetic modeling were performed using MONOLIX and Monte-Carlo simulations were conducted using MATLAB. The data was based from a previously published dataset where elderly patients, having multiple comorbidities, were administered a 50mg dose of metoprolol.</p><p><strong>Results: </strong>Metoprolol was modeled using a one-compartment model and resulted in the following population pharmacokinetic parameters: volume of distribution, V=38L (CV=155%), clearance rates, CL-Men=105L/hour and CL-Women=59.1L/hour (38%), time lag, Tlag=0.469 hour (CV=17%), and the absorption rate constant, Ka=0.235 hr<sup>-1</sup> (CV=23%).</p><p><strong>Conclusion: </strong>Gender stratified doses resulting in an equivalent systemic metoprolol exposure in geriatric patients have been identified. Metoprolol doses resulting a similar AUC in a healthy young male administered 50mg tablet were 15mg for geriatric women and 25mg for geriatric men. Further, Metoprolol doses of 25mg for geriatric women and 50mg for geriatric men resulted in an equivalent AUC to a healthy young males dosed with a 100mg tablet. A 15mg Metoprolol tablet may need to be compounded to account for the gender differences in Metoprolol pharmacokinetics.</p>","PeriodicalId":91507,"journal":{"name":"International journal of clinical pharmacology & toxicology","volume":"5 3","pages":"209-215"},"PeriodicalIF":0.0,"publicationDate":"2016-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959610/pdf/nihms794156.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34322788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations. 基于性别的老年人美托洛尔给药的人群药代动力学模型和模拟。
Pub Date : 2016-05-01 DOI: 10.19070/2167-910X-1600035
A. Eugene
INTRODUCTIONThis article seeks to clarify if gender-based differences occur in the pharmacokinetics of metoprolol in the elderly patients. There are a series of physiologic changes that occur in the elderly ranging from decreased hepatic blood flow to increased adiposity causing higher plasma concentrations at therapeutic doses as compared to the healthy young population.METHODSPopulation pharmacokinetic modeling were performed using MONOLIX and Monte-Carlo simulations were conducted using MATLAB. The data was based from a previously published dataset where elderly patients, having multiple comorbidities, were administered a 50mg dose of metoprolol.RESULTSMetoprolol was modeled using a one-compartment model and resulted in the following population pharmacokinetic parameters: volume of distribution, V=38L (CV=155%), clearance rates, CL-Men=105L/hour and CL-Women=59.1L/hour (38%), time lag, Tlag=0.469 hour (CV=17%), and the absorption rate constant, Ka=0.235 hr-1 (CV=23%).CONCLUSIONGender stratified doses resulting in an equivalent systemic metoprolol exposure in geriatric patients have been identified. Metoprolol doses resulting a similar AUC in a healthy young male administered 50mg tablet were 15mg for geriatric women and 25mg for geriatric men. Further, Metoprolol doses of 25mg for geriatric women and 50mg for geriatric men resulted in an equivalent AUC to a healthy young males dosed with a 100mg tablet. A 15mg Metoprolol tablet may need to be compounded to account for the gender differences in Metoprolol pharmacokinetics.
本文旨在澄清老年患者美托洛尔的药代动力学是否存在性别差异。与健康的年轻人群相比,在治疗剂量下,老年人发生一系列生理变化,从肝血流量减少到肥胖增加,导致血浆浓度升高。方法采用MONOLIX软件建立种群药代动力学模型,采用MATLAB软件进行蒙特卡罗模拟。该数据基于先前发表的数据集,其中患有多种合并症的老年患者给予50mg剂量的美托洛尔。结果美托洛尔的人群药动学参数为:分布容积V=38L (CV=155%),清除率cl -男性=105L/h, cl -女性=59.1L/h(38%),时差lag=0.469 h (CV=17%),吸收速率常数Ka=0.235 hr-1 (CV=23%)。结论:性别分层剂量导致老年患者全身美托洛尔暴露相等已被确定。美托洛尔剂量对健康年轻男性的AUC相似,给予50mg片剂的老年女性为15mg,老年男性为25mg。此外,老年女性服用25毫克美托洛尔,老年男性服用50毫克美托洛尔,其AUC与健康年轻男性服用100毫克片剂的AUC相当。15mg美托洛尔片可能需要复合,以解释美托洛尔药代动力学的性别差异。
{"title":"Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations.","authors":"A. Eugene","doi":"10.19070/2167-910X-1600035","DOIUrl":"https://doi.org/10.19070/2167-910X-1600035","url":null,"abstract":"INTRODUCTION\u0000This article seeks to clarify if gender-based differences occur in the pharmacokinetics of metoprolol in the elderly patients. There are a series of physiologic changes that occur in the elderly ranging from decreased hepatic blood flow to increased adiposity causing higher plasma concentrations at therapeutic doses as compared to the healthy young population.\u0000\u0000\u0000METHODS\u0000Population pharmacokinetic modeling were performed using MONOLIX and Monte-Carlo simulations were conducted using MATLAB. The data was based from a previously published dataset where elderly patients, having multiple comorbidities, were administered a 50mg dose of metoprolol.\u0000\u0000\u0000RESULTS\u0000Metoprolol was modeled using a one-compartment model and resulted in the following population pharmacokinetic parameters: volume of distribution, V=38L (CV=155%), clearance rates, CL-Men=105L/hour and CL-Women=59.1L/hour (38%), time lag, Tlag=0.469 hour (CV=17%), and the absorption rate constant, Ka=0.235 hr-1 (CV=23%).\u0000\u0000\u0000CONCLUSION\u0000Gender stratified doses resulting in an equivalent systemic metoprolol exposure in geriatric patients have been identified. Metoprolol doses resulting a similar AUC in a healthy young male administered 50mg tablet were 15mg for geriatric women and 25mg for geriatric men. Further, Metoprolol doses of 25mg for geriatric women and 50mg for geriatric men resulted in an equivalent AUC to a healthy young males dosed with a 100mg tablet. A 15mg Metoprolol tablet may need to be compounded to account for the gender differences in Metoprolol pharmacokinetics.","PeriodicalId":91507,"journal":{"name":"International journal of clinical pharmacology & toxicology","volume":"5 3 1","pages":"209-215"},"PeriodicalIF":0.0,"publicationDate":"2016-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68337879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
AT2 receptor: Its role in obesity associated hypertension. AT2受体在肥胖相关性高血压中的作用
Pub Date : 2012-10-01 Epub Date: 2012-10-16 DOI: 10.19070/2167-910X-120003
Quaisar Ali, Tahir Hussain

The renin-angiotensin system (RAS) is a hormonal cascade that acts together to regulate blood pressure. Angiotensin II (Ang II) is the major octapeptide of RAS and mediates its cellular and physiological actions by acting on AT1 and AT2 receptor. Most of the cellular and physiological actions of Ang II such as cellular growth and proliferation, vasoconstriction, antinatriuresis and increase in blood pressure are mediated via AT1 receptor. The functions associated with the AT2 receptors are less studied, in part, due to its lower expression in adult tissues. However, AT2 receptor has been suggested as functional antagonist of AT1 receptors and thereby opposes the actions of Ang II mediated via AT1 receptor. Thus, the activation of AT2 receptors has been shown to cause vasodilatation, natriuresis and decrease in blood pressure. After the discovery of the AT2 receptor in various parts of the kidney, including in proximal tubules, there has been an interest in establishing a link between the renal AT2 receptor, renal Na-excretion and blood pressure regulation. Earlier, we have reported that activation of renal AT2 receptors increases urinary Na excretion in obese Zucker rats, in part via inhibiting Na+/K+- ATPase (NKA) activity and stimulating nitric oxide/cGMP pathway in the proximal tubules. An impaired pressure natriuresis and increased AT1 receptor function is believed to be the cause of hypertension in obese Zucker rats and other animal models of obesity. In this review, we are focussing on the role of renin angiotensin system especially AT2 receptors in obesity associated hypertension.

肾素-血管紧张素系统(RAS)是一种激素级联反应,共同调节血压。血管紧张素II (Angiotensin II, Ang II)是RAS的主要八肽,通过作用于AT1和AT2受体介导RAS的细胞和生理活动。angii的大部分细胞和生理作用,如细胞生长和增殖、血管收缩、抗尿和血压升高,都是通过AT1受体介导的。与AT2受体相关的功能研究较少,部分原因是其在成人组织中的表达较低。然而,AT2受体被认为是AT1受体的功能性拮抗剂,从而对抗通过AT1受体介导的Ang II的作用。因此,AT2受体的激活已被证明可引起血管舒张、尿钠和血压降低。在肾脏的不同部位(包括近端小管)发现AT2受体后,人们对在肾脏AT2受体、肾脏na排泄和血压调节之间建立联系产生了兴趣。先前,我们报道了肾脏AT2受体的激活增加肥胖Zucker大鼠尿钠排泄,部分原因是通过抑制Na+/K+- atp酶(NKA)活性和刺激近端小管一氧化氮/cGMP途径。在肥胖的Zucker大鼠和其他肥胖动物模型中,血压尿钠功能受损和AT1受体功能增加被认为是导致高血压的原因。在这篇综述中,我们主要关注肾素血管紧张素系统特别是AT2受体在肥胖相关性高血压中的作用。
{"title":"AT<sub>2</sub> receptor: Its role in obesity associated hypertension.","authors":"Quaisar Ali,&nbsp;Tahir Hussain","doi":"10.19070/2167-910X-120003","DOIUrl":"https://doi.org/10.19070/2167-910X-120003","url":null,"abstract":"<p><p>The renin-angiotensin system (RAS) is a hormonal cascade that acts together to regulate blood pressure. Angiotensin II (Ang II) is the major octapeptide of RAS and mediates its cellular and physiological actions by acting on AT<sub>1</sub> and AT<sub>2</sub> receptor. Most of the cellular and physiological actions of Ang II such as cellular growth and proliferation, vasoconstriction, antinatriuresis and increase in blood pressure are mediated via AT<sub>1</sub> receptor. The functions associated with the AT<sub>2</sub> receptors are less studied, in part, due to its lower expression in adult tissues. However, AT<sub>2</sub> receptor has been suggested as functional antagonist of AT<sub>1</sub> receptors and thereby opposes the actions of Ang II mediated via AT<sub>1</sub> receptor. Thus, the activation of AT<sub>2</sub> receptors has been shown to cause vasodilatation, natriuresis and decrease in blood pressure. After the discovery of the AT<sub>2</sub> receptor in various parts of the kidney, including in proximal tubules, there has been an interest in establishing a link between the renal AT<sub>2</sub> receptor, renal Na-excretion and blood pressure regulation. Earlier, we have reported that activation of renal AT<sub>2</sub> receptors increases urinary Na excretion in obese Zucker rats, in part via inhibiting Na<sup>+</sup>/K<sup>+</sup>- ATPase (NKA) activity and stimulating nitric oxide/cGMP pathway in the proximal tubules. An impaired pressure natriuresis and increased AT<sub>1</sub> receptor function is believed to be the cause of hypertension in obese Zucker rats and other animal models of obesity. In this review, we are focussing on the role of renin angiotensin system especially AT<sub>2</sub> receptors in obesity associated hypertension.</p>","PeriodicalId":91507,"journal":{"name":"International journal of clinical pharmacology & toxicology","volume":"1 1","pages":"15-19"},"PeriodicalIF":0.0,"publicationDate":"2012-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004927/pdf/nihms811995.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34358240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
International journal of clinical pharmacology & toxicology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1